Second-generation travoprost intracameral implant for open-angle glaucoma and ocular hypertension
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
PHASE2; PHASE3 · Glaukos Corporation · NCT07075718
This trial will test whether a second-generation travoprost implant placed inside the eye lowers eye pressure better than timolol eye drops in people with open-angle glaucoma or ocular hypertension.
Quick facts
| Phase | PHASE2; PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 610 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Glaukos Corporation (industry) |
| Locations | 3 sites (Grand Junction, Colorado and 2 other locations) |
| Trial ID | NCT07075718 on ClinicalTrials.gov |
What this trial studies
This randomized Phase 2/3 trial compares a second-generation travoprost intracameral implant to timolol 0.5% eye drops given twice daily in adults with open-angle glaucoma or ocular hypertension. Participants are randomized to receive the implant (with sham and placebo controls as appropriate) or topical timolol and are followed for safety and intraocular pressure (IOP) lowering outcomes. Key eligibility includes a diagnosis of open-angle glaucoma or ocular hypertension and excludes eyes with prior incisional glaucoma surgery, prior argon laser trabeculoplasty (ALT), or prior minimally invasive glaucoma surgery (MIGS). The study collects both efficacy endpoints (IOP reduction) and safety data related to the implant and ocular procedures.
Who should consider this trial
Good fit: Adults with open-angle glaucoma or ocular hypertension who have not had prior incisional glaucoma surgery, ALT, or MIGS in the study eye are appropriate candidates for this protocol.
Not a fit: Patients with prior incisional glaucoma surgery, prior ALT, or prior MIGS in the study eye are excluded and would not be expected to benefit from this study.
Why it matters
Potential benefit: If successful, the implant could provide sustained IOP lowering without daily drops, improving adherence and potentially reducing glaucoma progression risk.
How similar studies have performed: Earlier-generation intracameral prostaglandin implants, including travoprost devices, have demonstrated IOP lowering versus topical therapy in prior trials, though this second-generation implant is a newer iteration undergoing further testing.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Where this trial is running
Grand Junction, Colorado and 2 other locations
- Glaukos Investigative Site — Grand Junction, Colorado, United States (RECRUITING)
- Glaukos Investigative Site — Oklahoma City, Oklahoma, United States (RECRUITING)
- Glaukos Clinical Site — El Paso, Texas, United States (RECRUITING)
Study contacts
- Study coordinator: Study Director
- Email: ClinicalResearch@glaukos.com
- Phone: 949-739-8749
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glaucoma, open-angle glaucoma, ocular hypertension